CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners.

GlaxoSmithKline and CureVac announced a new EUR 150M collaboration to jointly develop next-generation mRNA vaccines for COVID-19 "with the potential for a multi-valent approach to address multiple emerging variants in one vaccine."

Three weeks ago, we suggested that investors stay the course with healthcare and biotech because of potential volatility with the 2020 Election and COVID-19 cases spiking. We have seen a big shift toward energy, financial, and industrial stocks.

Today we a quarterly report and news on the global stocks we have our eyes on.